Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis: serum inflammatory biomarkers, clinical efficacy, and microbiological eradication

References

• KimNLeeperKVJrEpidemiology of chronic bronchitis and acute infective exacerbations of chronic bronchitisSemin Respir Crit Care Med2000212737816088720
   PubMed Web of Science ®Google Scholar
• BousquetJKileyJBatemanEDPrioritised research agenda for prevention and control of chronic respiratory diseasesEur Respir J2010365995100120223919
   PubMed Web of Science ®Google Scholar
• MurrayCJLopezADAlternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease StudyLancet19973499064149815049167458
   PubMed Web of Science ®Google Scholar
• AnthonisenNRManfredaJWarrenPCHershfieldECHardingGKNelsonNAAntibiotic therapy in exacerbations of chronic obstructive pulmonary diseaseAnn Intern Med198710621962043492164
   PubMed Web of Science ®Google Scholar
• SeemungalTADonaldsonGCPaulEABestallJCJeffriesDJWedzichaJAEffect of exacerbation on quality of life in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19981575 Pt 1141814229603117
   PubMed Web of Science ®Google Scholar
• Soler-CataluñaJJMartínez-GarcíaMARomán SánchezPSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax2005601192593116055622
   PubMed Web of Science ®Google Scholar
• DonaldsonGCSeemungalTABhowmikAWedzichaJARelationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax2002571084785212324669
   PubMed Web of Science ®Google Scholar
• KannerREAnthonisenNRConnettJELung Health Study Research GroupLower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health studyAm J Respir Crit Care Med2001164335836411500333
   PubMed Web of Science ®Google Scholar
• DonaldsonGCHurstJRSmithCJHubbardRBWedzichaJAIncreased risk of myocardial infarction and stroke following exacerbation of COPDChest201013751091109720022970
   PubMed Web of Science ®Google Scholar
• ReynoldsHYChronic obstructive pulmonary disease, chronic bronchitis, and acute exacerbationsMandellGLBennettJEDolinRPrinciples and Practice of Infectious Disease6th edPhiladelphia, PAElsevier Churchill Livingstone2005
   Google Scholar
• Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD)2011 Available from: http://www.goldcopd.orgAccessed November 10, 2012
   Google Scholar
• ReillyJJCOPD and declining FEV1 – time to divide and conquer?N Engl J Med2008359151616161818836214
   PubMed Web of Science ®Google Scholar
• SethiSMurphyTFInfection in the pathogenesis and course of chronic obstructive pulmonary diseaseN Engl J Med2008359222355236519038881
   PubMed Web of Science ®Google Scholar
• HayesDJrMeyerKCAcute exacerbations of chronic bronchitis in elderly patients: pathogenesis, diagnosis and managementDrugs Aging200724755557217658907
   PubMed Web of Science ®Google Scholar
• MensaJTrillaAShould patients with acute exacerbation of chronic bronchitis be treated with antibiotics? Advantages of the use of fluoroquinolonesClin Microbiol Infect200612 Suppl 3425416669928
   PubMed Web of Science ®Google Scholar
• SethiSPathogenesis and treatment of acute exacerbations of chronic obstructive pulmonary diseaseSemin Respir Crit Care Med200526219220316088436
   PubMed Web of Science ®Google Scholar
• ChibaSOhtaHAbeKThe diagnostic value of the interstitial biomarkers KL-6 and SP-D for the degree of fibrosis in combined pulmonary fibrosis and emphysemaPulm Med2012201249296022530118
   PubMedGoogle Scholar
• AraiSKurasawaKMaezawaROwadaTOkadaHFukudaTMarked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis in patients with active interstitial pneumonia associated with polymyositis/dermatomyositisMod Rheumatol9172012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• IshikawaNHattoriNYokoyamaAKohnoNUtility of KL-6/MUC1 in the clinical management of interstitial lung diseasesRespir Investig2012501313
   PubMedGoogle Scholar
• BlasiFBulfoniAConciaCAttualita’ nella gestione delle infezioni delle basse vie respiratorie in medicina internaManagement of lower respiratory tract infections in internal medicineItalian Journal of Medicine2012414253 Italian
   Google Scholar
• PetitpretzPChonéCTrémolièresFInvestigator Study GroupLevofloxacin 500 mg once daily versus cefuroxime 250 mg twice daily in patients with acute exacerbations of chronic obstructive bronchitis: clinical efficacy and exacerbation-free intervalInt J Antimicrob Agents2007301525917512704
   PubMed Web of Science ®Google Scholar
• Alvarez-SalaJLKardosPMartínez-BeltránJCoronelPAguilarLClinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetilAntimicrob Agents Chemother20065051762176716641447
   PubMed Web of Science ®Google Scholar
• WilsonRLanganCBallPBatemanKPypstraRGemifloxacin 207 Clinical Study GroupOral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitisRespir Med200397324224912645831
   PubMed Web of Science ®Google Scholar
• WeissLROpen-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitisClin Ther20022491414142512380633
   PubMed Web of Science ®Google Scholar
• AnzuetoABishaiWRPottumarthySRole of oral extended-spectrum cephems in the treatment of acute exacerbation of chronic bronchitisDiagn Microbiol Infect Dis200757Suppl 331S38S17349461
   PubMed Web of Science ®Google Scholar
• DuboisJSt-PierreCIn vitro study of the post-antibiotic effect and the bactericidal activity of Cefditoren and ten other oral antimicrobial agents against upper and lower respiratory tract pathogensDiagn Microbiol Infect Dis200037318719310904192
   PubMed Web of Science ®Google Scholar
• GraciaMDíazCCoronelPAntimicrobial susceptibility of Streptococcus pyogenes in Central, Eastern, and Baltic European Countries, 2005 to 2006: the cefditoren surveillance programDiagn Microbiol Infect Dis2009641525619232860
   PubMed Web of Science ®Google Scholar
• TemperaGFurneriPMCarloneNAAntibiotic susceptibility of respiratory pathogens recently isolated in Italy: focus on cefditorenJ Chemother201022315315920566418
   PubMed Web of Science ®Google Scholar
• TemperaGFurneriPMFerrantiCIn vitro activity of cefditoren versus other antibiotics against S. pneumoniae clinical strains isolated in ItalyInt J Immunopathol Pharmacol201023383384020943054
   PubMed Web of Science ®Google Scholar
• GraciaMDíazCCoronelPAntimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis isolates in eight Central, East and Baltic European countries in 2005–2006: results of the Cefditoren Surveillance StudyJ Antimicrob Chemother20086151180118118316820
   PubMed Web of Science ®Google Scholar
• García-de-LomasJLermaMCebriánLInfluence of Haemophilus influenzae beta-lactamase production and/or ftsI gene mutations on in vitro activity of and susceptibility rates to aminopenicillins and second- and third-generation cephalosporinsInt J Antimicrob Agents200730219019217459665
   PubMed Web of Science ®Google Scholar
• BarberánJAguilarLGiménezMJUpdate on the clinical utility and optimal use of cefditorenInt J Gen Med2012545546422675264
   PubMedGoogle Scholar
• SorianoFGiménezMJAguilarLCefditoren in upper and lower community-acquired respiratory tract infectionsDrug Des Devel Ther201158594
   PubMed Web of Science ®Google Scholar
• GranizoJJGiménezMJBarberánJCoronelPGimenoMAguilarLEfficacy of cefditoren in the treatment of upper respiratory tract infections: a pooled analysis of six clinical trials. SpanishRev Esp Quimioter20082111421 Spanish18443928
   PubMed Web of Science ®Google Scholar
• GranizoJJAguilarLGimenezMJCoronelPGimenoMPrietoJSafety profile of cefditoren. A pooled analysis of data from clinical trials in community-acquired respiratory tract infectionsRev Esp Quimioter20092225761 Spanish19544097
   PubMed Web of Science ®Google Scholar
• ShahPMMaesenFPDolmannAVetterNFissEWeschRLevofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind studyJ Antimicrob Chemother199943452953910350383
   PubMed Web of Science ®Google Scholar
• YanbaevaDGDentenerMASpruitMAIL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: a case-control studyBMC Med Genet2009102319272152
   PubMed Web of Science ®Google Scholar
• RinconMIrvinCGRole of IL-6 in asthma and other inflammatory pulmonary diseasesInt J Biol Sci2012891281129023136556
   PubMed Web of Science ®Google Scholar
• Grubek-JaworskaHPaplińskaMHermanowicz-SalamonJIL-6 and IL-13 in induced sputum of COPD and asthma patients: correlation with respiratory testsRespiration201284210110722311051
   PubMed Web of Science ®Google Scholar
• CelliBRLocantoreNYatesJInflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2012185101065107222427534
   PubMed Web of Science ®Google Scholar
• AgustiAEdwardsLDRennardSIPersistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotypePLoS One201275e3748322624038
   PubMed Web of Science ®Google Scholar
• WedzichaJASeemungalTAMacCallumPKAcute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levelsThromb Haemost200084221021510959691
   PubMed Web of Science ®Google Scholar
• NathaniNPerkinsGDTunnicliffeWMurphyNManjiMThickettDRKerbs von Lungren 6 antigen is a marker of alveolar inflammation but not of infection in patients with acute respiratory distress syndromeCrit Care2008121R1218269741
   PubMed Web of Science ®Google Scholar
• SatoHCallisterMEMumbySKL-6 levels are elevated in plasma from patients with acute respiratory distress syndromeEur Respir J200423114214514738246
   PubMed Web of Science ®Google Scholar
• IshizakaAMatsudaTAlbertineKHElevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndromeAm J Physiol Lung Cell Mol Physiol20042866L1088L109412959931
   PubMed Web of Science ®Google Scholar
• DoishitaSInokumaSAsashimaHSerum KL-6 level as an indicator of active or inactive interstitial pneumonitis associated with connective tissue diseasesIntern Med201150232889289222129503
   PubMed Web of Science ®Google Scholar
• SatohHKurishimaKIshikawaHOhtsukaMIncreased levels of KL-6 and subsequent mortality in patients with interstitial lung diseasesJ Intern Med2006260542943417040248
   PubMed Web of Science ®Google Scholar
• YokoyamaAKondoKNakajimaMPrognostic value of circulating KL-6 in idiopathic pulmonary fibrosisRespirology200611216416816548901
   PubMed Web of Science ®Google Scholar
• IshikawaNMazurWToljamoTAgeing and long-term smoking affects KL-6 levels in the lung, induced sputum and plasmaBMC Pulm Med2011112221569324
   PubMed Web of Science ®Google Scholar
• IshikawaNHattoriNTanakaSLevels of surfactant proteins A and D and KL-6 are elevated in the induced sputum of chronic obstructive pulmonary disease patients: a sequential sputum analysisRespiration2011821101821474912
   PubMed Web of Science ®Google Scholar
• HenryDCPolingTLBettisRBA double-blind, randomized study of cefditoren vs cefuroxime for AECBJ Respir Dis200122 Suppl 86974
   Google Scholar
• PfallerMAEhrhardtAFJonesRNFrequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environmentAm J Med2001111Suppl 9A4S12S11755437
   PubMed Web of Science ®Google Scholar
• SlamaTGAminABruntonSAA clinician’s guide to the appropriate and accurate use of antibiotics: the Council for Appropriate and Rational Antibiotic Therapy (CARAT) criteriaAm J Med2005118Suppl 7A1S6S15993671
   PubMed Web of Science ®Google Scholar
• MartinezFJAnzuetoAAppropriate outpatient treatment of acute bacterial exacerbations of chronic bronchitisAm J Med2005118Suppl 7A39S44S15993676
   PubMed Web of Science ®Google Scholar
• ScaglioneFBertazzoni MinelliEDe SarroAThe Charta of Milan: basic criteria for the appropriate and accurate use of antibiotics: recommendations of the Italian Society of ChemotherapyJ Chemother200921547548119933037
   PubMed Web of Science ®Google Scholar
• Levy-HaraGAmábile-CuevasCFGouldI“Ten Commandments” for the appropriate use of antibiotics by the practicing physician in an outpatient settingFront Microbiol2011223022164154
   PubMed Web of Science ®Google Scholar
• CanutAMartın-HerreroJELaboraAMaortuaHWhat are the most appropriate antibiotics for the treatment of acute exacerbation of chronic obstructive pulmonary disease? A therapeutic outcomes modelJ Antimicrob Chemother200760360561217595285
   PubMed Web of Science ®Google Scholar
• BlasiFConciaEMazzeiTRole of the oral beta-lactams in the treatment of exacerbations of chronic bronchitis: critical analysis and therapeutic recommendationsJ Chemother201022 Suppl 133021097386
   PubMed Web of Science ®Google Scholar
• PugiALongoLBartoloniACardiovascular and metabolic safety profiles of the fluoroquinolonesExpert Opin Drug Saf2012111536921958023
   PubMed Web of Science ®Google Scholar
• LapiFWilcheskyMKezouhABenistyJIErnstPSuissaSFluoroquinolones and the risk of serious arrhythmia: a population-based studyClin Infect Dis201255111457146522865870
   PubMed Web of Science ®Google Scholar
• PatersonJMMamdaniMMMannoMJuurlinkDNfor the Canadian Drug Safety and Effectiveness Research NetworkFluoroquinolone therapy and idiosyncratic acute liver injury: a population-based studyCMAJ2012184141565157022891208
   PubMed Web of Science ®Google Scholar
• EtminanMForooghianFBrophyJMBirdSTMaberleyDOral fluoroquinolones and the risk of retinal detachmentJAMA2012307131414141922474205
   PubMed Web of Science ®Google Scholar
• StahlmannRLodeHSafety considerations of fluoroquinolones in the elderly: an updateDrugs Aging201027319320920210367
   PubMed Web of Science ®Google Scholar
• LodeHSafety and tolerability of commonly prescribed oral antibiotics for the treatment of respiratory tract infectionsAm J Med2010123Suppl 4S26S3820350633
   PubMed Web of Science ®Google Scholar
• WoodheadMBlasiFEwigSGuidelines for the management of adult lower respiratory tract infections – summaryClin Microbiol Infect201117 Suppl 612421951384
   PubMed Web of Science ®Google Scholar